news
AI drug prediction: better data beats bigger models
Results from the OpenADMET AI competition showed that smaller, higher-quality datasets led to more accurate predictions for drug metabolism than larger, less curated ones. This challenges the 'bigger is always better' AI dogma for drug discovery. The findings indicate a shift in strategy for biopharma companies developing AI tools to identify promising new drug candidates faster.
Results from the OpenADMET AI competition showed that smaller, higher-quality datasets led to more accurate predictions for drug metabolism than larger, less curated ones. This challenges the 'bigger is always better' AI dogma for drug discovery. The findings indicate a shift in strategy for biopharma companies developing AI tools to identify promising new drug candidates faster.
The architecture take
Turns out, even AI can't make sense of garbage data. This competition proved that when it comes to predicting how a drug breaks down in your body (that's 'metabolism' for the uninitiated), precision beats sheer volume any day. It's not about training a model on every molecule ever, it's about giving it the right molecules. For pharma, this means less wasted time and money chasing compounds that look good on paper but fall apart in phase one. For you, it means a slightly faster, slightly more efficient path to seeing new, effective drugs for things like metabolic disorders or mental health conditions actually hit the market. Quality over quantity, the oldest trick in the book, still wins — even with fancy AI.